Am­gen spin­out Kezar hits PhII hur­dle, all eyes on June read­out for drug’s oth­er study

A 2015 spin­out from Am­gen’s $10.4 bil­lion Onyx Phar­ma­ceu­ti­cals pur­chase has hit a mid-stage road­block.

Kezar Life Sci­ences’ lead as­set, ze­tomip­zomib, showed no dif­fer­en­ti­a­tion from place­bo in a mid-stage study in pa­tients with two rare mus­cle in­flam­ma­tion and skin dis­eases. The Phase II PRE­SIDIO tri­al flop was seen in pa­tients with der­mato­myosi­tis, DM, and polymyosi­tis, or PM, which are two chron­ic in­flam­ma­to­ry au­toim­mune dis­eases that im­pact about 30,000 to 120,000 peo­ple in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER